Redhill Biopharma
RDHL
$0.46
Share price
1.33%
Change (1 day)
-79.18%
Change (1 year)
Categories
P/S ratio for Redhill Biopharma (RDHL)
P/S ratio as of June 2024 (TTM): 0.4086
According to Redhill Biopharma's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.408579. At the end of 2023 the company had a P/S ratio of 0.0990.
P/S ratio history for Redhill Biopharma from 2013 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 0.0990 | -52.18% |
| 2022 | 0.2071 | -86.87% |
| 2021 | 1.58 | -66.69% |
| 2020 | 4.73 | -86.09% |
| 2019 | 34.0 | 80.69% |
| 2018 | 18.8 | -30.98% |
| 2017 | 27.3 | -98.46% |
| 2016 | > 1000 | -96.76% |
| 2015 | > 1000 | 326648.98% |
| 2014 | 16.7 | -99.74% |
| 2013 | > 1000 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 2.38 | 482.56% | 🇫🇷 France |
 Merck MRK | 5.19 | 1,171.07% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.39 | 484.86% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | 1.20 | 192.75% | 🇮🇱 Israel |
 Taro Pharmaceutical TARO | 2.63 | 542.75% | 🇮🇱 Israel |